12 July 2016 EMA/HMPC/7685/2013 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on Allium sativum L., bulbus Draft Initial assessment Discussion in Working Party on European Union monographs and

January 2013

European Union list (MLWP)

March 2013 July 2013 March 2014 July 2015 February 2016 April 2016

Adopted by Committee on Herbal Medicinal Products (HMPC) for release

12 July 2016

for consultation Start of public consultation

25 July 2016

End of consultation (deadline for comments). Comments should be

31 October 2016

provided using this template to [email protected]> Rediscussion in MLWP Adoption by HMPC Keywords

Herbal medicinal products; HMPC; European Union herbal monographs; traditional use; Allium sativum L., bulbus; Allii sativi bulbus; garlic

BG (bulgarski): Чесън, луковица

LT (lietuvių kalba): Česnakai

CS (čeština): česneková cibule

LV (latviešu valoda): Ķiploka sīpols

DA (dansk): Hvidløg

MT (Malti): Basla tat-Tewm

DE (Deutsch): Knoblauchzwiebel

NL (Nederlands): Knoflook

EL (elliniká): Βολβός σκορόδου

PL (polski): Czosnek

EN (English): Garlic

PT (português): Alho, bolbo de

ES (español): Ajo, bulbo de

RO (română): bulb de usturoi

ET (eesti keel): küüslauk

SK (slovenčina): Cibuľa cesnaku (cesnak)

FI (suomi): valkosipuli

SL (slovenščina): čebulica česna

FR (français): Ail (bulbe d')

SV (svenska): Vitlök, lök

HR (hrvatski): češnjakova lukovica

IS (íslenska):

HU (magyar): fokhagyma

NO (norsk): Hvitløk

IT (italiano): Aglio bulbo 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

European Union herbal monograph on Allium sativum L., bulbus 1. Name of the medicinal product To be specified for the individual finished product.

2. Qualitative and quantitative composition 1, 2 Well-established use

Traditional use With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Allium sativum L., bulbus; (garlic) i) Herbal substance Not applicable ii) Herbal preparations a) Powdered herbal substance b) Liquid extract from fresh bulb (DER 2-3:1), extraction solvent rapeseed oil, refined c)

Dry extract (DER 5:1), extraction solvent ethanol 34% V/V

3. Pharmaceutical form Well-established use

Traditional use Herbal preparations in solid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

1

The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. 2

The material complies with the Ph. Eur. monograph (ref.: 12163)

European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013

Page 4/7

4. Clinical particulars 4.1. Therapeutic indications Well-established use

Traditional use Indication 1) Traditional herbal medicinal product used as an adjuvant for the prevention of atherosclerosis. Indication 2) Traditional herbal medicinal product used for the relief of the symptoms of cold. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration Well-established use

Traditional use Posology Indication 1) Adults and elderly a) Powdered herbal substance single dose: 300 mg to 750 mg Daily dose: 900-1380 mg divided into 3 to 5 b) Liquid extract: Single doses: 110-220 mg 4 times daily Daily dose: 440-880 mg The use in children and adolescents under 18 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’). Indication 2) Adolescents, adults and elderly c)

Dry extract: Single dose: 100-200 mg 1-2 times daily Daily dose: 100-400 mg

The use in children under 12 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’).

European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013

Page 5/7

Well-established use

Traditional use Duration of use Indication 1) No restrictions to the duration of use. Indication 2) If the symptoms persist longer than one week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration Oral use

4.3. Contraindications Well-established use

Traditional use Hypersensitivity to the active substance. Patients under saquinavir/ritonavir therapy (see also section 4.5 Interactions).

4.4. Special warnings and precautions for use Well-established use

Traditional use

.

Garlic consumption should be avoided 7 days before surgery because of the post-operative bleeding risk. Indication 1) The use in children and adolescents under 18 years of age has not been established due to lack of data. Indication 2) The use in children under 12 years of age has not been established due to lack of adequate data. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013

Page 6/7

4.5. Interactions with other medicinal products and other forms of interaction Well-established use

Traditional use Garlic preparations should be used with caution in patients taking oral anticoagulation therapy and/or anti-platelet therapy because they may increase bleeding times. Concomitant use with saquinavir/ritonavir is contraindicated because of the risks of decrease in plasma concentration, loss of virological response and possible resistance to one or more components of the antiretroviral regime (see also section 4.3 Contraindications).

4.6. Fertility, pregnancy and lactation Well-established use

Traditional use Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Studies in animals have shown effects on fertility (see section 5.3 ‘Preclinical safety data’).

4.7. Effects on ability to drive and use machines Well-established use

Traditional use No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects Well-established use

Traditional use - Malodorous breath or body odour, abdominal pain, bloating, flatulence, fullness, anorexia - Allergic reactions such as contact dermatitis, conjunctivitis, rhinitis, or bronchospasms, sometimes severe - Headache, dizziness, and profuse sweating - Bleeding The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care

European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013

Page 7/7

Well-established use

Traditional use practitioner should be consulted.

4.9. Overdose Well-established use

Traditional use No case of overdose has been reported.

5. Pharmacological properties 5.1. Pharmacodynamic properties Well-established use

Traditional use Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties Well-established use

Traditional use Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data Well-established use

Traditional use Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity and genotoxicity have not been performed. Tests on carcinogenicity have not been performed. Testicular toxicity (e.g. spermatogenesis impairment) was reported in rats treated for 30 days with crude garlic and in rats treated for 70 days with 50 mg of garlic powder. A decrease in testosterone occurs concomitantly; a NOAEL was not determined for the garlic powder. These effects on male rat fertility were observed at approximately twice the maximal human daily dose.

European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013

Page 8/7

6. Pharmaceutical particulars Well-established use

Traditional use Not applicable

7. Date of compilation/last revision 12 July 2106

European Union herbal monograph on Allium sativum L., bulbus EMA/HMPC/7685/2013

Page 9/7

Draft European Union herbal monograph on Allium sativum L., bulbus

Jul 12, 2016 - Send a question via our website www.ema.europa.eu/contact. © European Medicines Agency ... Name of the medicinal product. To be specified for the ... With regard to the registration application of. Article 16d(1) of Directive ...

135KB Sizes 3 Downloads 233 Views

Recommend Documents

Draft European Union herbal monograph on Glycine max (L.) Merr ...
Jul 12, 2016 - Send a question via our website www.ema.europa.eu/contact. © European .... Full baths are contraindicated in cases of open wounds, large ...

European Union herbal monograph on Mentha x piperita L., folium
Jan 31, 2017 - Page 2/7. Keywords. Herbal medicinal products; HMPC; European Union herbal monographs; ... Article 16d(1) of Directive 2001/83/EC.

Final European Union herbal monograph on Valeriana officinalis L ...
Feb 2, 2016 - mild symptoms of mental stress and to aid sleep. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use. 4.2. Posology and method of administration4. Well-estab

Final European Union herbal monograph on Polygonum aviculare L ...
Apr 5, 2016 - Send a question via our website www.ema.europa.eu/contact. © European Medicines Agency ... Start of public consultation. 19 October 2015.

European Union herbal monograph on Arctostaphylos uva-ursi (L ...
Mar 28, 2017 - EMA/HMPC/750269/2016. Committee on ... November 2016. January 2017 .... In absence of sufficient data, the use during lactation is not ...

Community herbal monograph on Cimicifuga racemosa - European ...
Nov 25, 2010 - LT (lietuvių kalba):. LV (latvieÅ¡u valoda): Sudrabsveces saknenis. MT (malti): Riżoma tal-Koħox. NL (nederlands): Zilverkaars. PL (polski): ...

Opinion of the HMPC on a European Union herbal monograph on ...
An agency of the European Union. Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website www.ema.europa.eu/ ...

Opinion of the HMPC on a European Union herbal monograph on ...
Send a question via our website www.ema.europa.eu/contact ... The HMPC, in accordance with Article 16h(3) of Directive 2001/83/EC, as amended, and as set ...

HMPC meeting report on European Union herbal monographs ...
Apr 19, 2018 - Upon recommendation from the MLWP, the HMPC adopted after systematic review the following final revised EU herbal monographs:.

HMPC meeting report on European Union herbal monographs ...
Jul 18, 2016 - Send a question via our website www.ema.europa.eu/contact. © European Medicines .... (mandate start 12/07/2016). The new mandate and ...

HMPC meeting report on European Union herbal monographs ...
Jul 18, 2016 - products in applications for marketing authorisation (bibliographical and mixed ... and supporting documents', proposals on update of existing template for EU herbal monographs, ... E-mail: [email protected].

HMPC meeting report on European Union herbal monographs ...
Feb 6, 2017 - The drafting group started the review of the herbal specification guideline in line with the quality guideline revision as well as of the reflection ...

HMPC meeting report on European Union herbal monographs ...
Feb 22, 2018 - The committee welcomed Erika Svedlund as new member from Sweden and Katarzyna Tomaszewska as new Polish alternate. Revised European Union herbal monographs. Upon recommendation from the MLWP, the HMPC adopted after systematic review th

HMPC meeting report on European Union herbal monographs ...
Jun 14, 2016 - Call for scientific data (systematic monograph review). In April the HMPC had agreed to initiate the systematic review of 13 herbal substances ...

HMPC meeting report on European Union herbal monographs ...
Mar 27, 2018 - Upon recommendation from the MLWP, the HMPC adopted after systematic review the following final revised EU herbal monographs: •. Revised EU herbal monograph on Agni casti fructus (by majority). •. Revised EU herbal monograph on Cal

229-32 Effect of garlic (Allium sativum L.) extract on ...
The mean lead concentration in liver, kidneys, brain and bone of lead exposed rats was 2.943+/-. 0.206, 4.780+/-0.609, 1.019+/-0.100 and 44.075+/-2.60 microg ...

Allium cepa L. - Dialnet
los factores que más limitan la producción de cebolla se consideran, ... Email: [email protected] (J. Amaya) ... el nutriente más limitante, pues contribuye.

Pisum sativum L.
free amino acid reduced as maturation of seed advanced but the seed protein content found to be ... Quality seed not only provides the bridge between.

The-European-Union-And-Russia-The-European-Union-Series.pdf ...
institutional development of EU-Russia relations from three perspectives: European studies, Russian studies and International. Relations, including Foreign ...

Regulatory Q&A on herbal medicinal products - European Medicines ...
Sep 20, 2016 - (R6) What kinds of safety data are required for applications ..... has to be demonstrated by using appropriate analytical data, for example.

The European Union
identity, a uniquely European sense of self and conception of the good life, has ... Email: [email protected] .... that nation states have appealed to but by subscription to democratic values and ...... European Parliament Press Service.

Draft guideline on multiplicity issues in clinical trials - European ...
Apr 1, 2017 - 360 usually be included with the objective of adding weight in support ..... with composite outcome measures from a regulatory point of view is, ...